Skip to content

RARE

Ultragenyx Pharmaceutical Inc.

Key figures

MetricLast 12 months5-year CAGR
Revenue$730M+19.9%
Gross profit$596M+16.3%
Operating income−$467M—
Net income−$524M—
EPS−$5.19—
Free cash flow−$442M—